Gut microbiome and metabolic dysfunction-associated steatotic liver disease: Pathogenic role and potential for therapeutics
Articolo
Data di Pubblicazione:
2024
Citazione:
Garcia-Mateo, S., Rondinella, D., Ponziani, F. R., Miele, L., Gasbarrini, A., Cammarota, G., Lanas, Á., Gomollón, F., Gut microbiome and metabolic dysfunction-associated steatotic liver disease: Pathogenic role and potential for therapeutics, <>, N/A; 72 (N/A): N/A-N/A. [doi:10.1016/j.bpg.2024.101924] [https://hdl.handle.net/10807/336659]
Abstract:
Gut microbiota plays key functions in the human body, and its alteration is associated with several human disorders. Moreover, its manipulation is being investigated as a potential therapeutic strategy. In this narrative review we will dissect the involvement of the gut microbiota and of the gut–liver axis on metabolic dysfunction-associated steatotic liver disease (MASLD). Additionally, we will review the effects of lifestyle interventions commonly used for MASLD (i.e. Mediterranean diet and physical exercise) on gut microbiome, to understand if their beneficial effect can be microbially mediated. Finally, we will discuss the role and the available evidence of therapeutic microbiome modulators, including prebiotics, probiotics, symbiotics, and fecal microbiota transplantation (FMT), in the management of MASLD.
Tipologia CRIS:
Articolo in rivista, Nota a sentenza
Keywords:
Fecal microbiota transplantation; Metabolic dysfunction-associated steatotic liver disease; Microbioma; Prebiotics; Probiotics; Synbiotics
Elenco autori:
Garcia-Mateo, Sandra; Rondinella, Debora; Ponziani, Francesca Romana; Miele, Luca; Gasbarrini, Antonio; Cammarota, Giovanni; Lanas, Ángel; Gomollón, Fernando
Link alla scheda completa:
Pubblicato in: